SOM Stock Overview
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SomnoMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.25 |
| 52 Week High | AU$0.53 |
| 52 Week Low | AU$0.20 |
| Beta | 1.38 |
| 11 Month Change | -34.87% |
| 3 Month Change | -36.54% |
| 1 Year Change | n/a |
| 33 Year Change | -89.22% |
| 5 Year Change | -91.55% |
| Change since IPO | -91.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOM | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -14.7% | 0.5% | 0.9% |
| 1Y | n/a | 14.8% | 18.4% |
Return vs Industry: Insufficient data to determine how SOM performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how SOM performed against the Australian Market.
Price Volatility
| SOM volatility | |
|---|---|
| SOM Average Weekly Movement | 15.2% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: SOM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: SOM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Amrita Blickstead | somnomed.com/au/ |
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances.
SomnoMed Limited Fundamentals Summary
| SOM fundamental statistics | |
|---|---|
| Market cap | AU$55.11m |
| Earnings (TTM) | -AU$12.24m |
| Revenue (TTM) | AU$91.65m |
0.6x
P/S Ratio-4.5x
P/E RatioIs SOM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOM income statement (TTM) | |
|---|---|
| Revenue | AU$91.65m |
| Cost of Revenue | AU$36.52m |
| Gross Profit | AU$55.13m |
| Other Expenses | AU$67.37m |
| Earnings | -AU$12.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 60.15% |
| Net Profit Margin | -13.36% |
| Debt/Equity Ratio | 2.3% |
How did SOM perform over the long term?
See historical performance and comparison